Trials / No Longer Available
No Longer AvailableNCT05131438
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- EQRx International, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- —
Summary
This program is intended to provide access to sugemalimab for participants with R/R ENKTL, after their disease failed to respond to prior treatment regimen(s), preceding marketing authorization by the local regulatory agency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sugemalimab | sugemalimab (Anti-PD-L1 antibody) |
Timeline
- First posted
- 2021-11-23
- Last updated
- 2023-03-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05131438. Inclusion in this directory is not an endorsement.